News

Newron picks up Neuronova AB
Enlarge image

BusinessItalySweden

Newron picks up Neuronova AB

14.06.2012 - Italian neuroscience specialist Newron Pharmaceuticals S.p.A. acquires the Stockholm-based Neuronova AB in a deal worth €15.4m

Bresso/Stockholm – The transaction will add two new Phase II compounds from NeuroNova to Newron’s CNS portfolio. sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease (PD) that is designed to act on neural stem and progenitor cells in the brain. In a Phase I/II trial in patients with PD, the active ingredient platelet-derived growth factor BB demonstrated preliminary beneficial effects on biochemical markers of the degenerating dopamine system in PD patients. The second compound, sNN0029 with the active ingredient vascular endothelial growth factor, is intended for the treatment of amyotrophic lateral sclerosis (ALS) and is currently evaluated in a Phase I/II trial.

At the transaction close, Newron will benefit by cash and commitments of up to €16m. These funds are sufficient to provide for a Phase II study in PD as well as the ongoing Phase I/II study in ALS, in addition to the related corporate operations. The biggest investors in Neuronova, Investor and Healthcap, will also take a stake in Newron. Both will send a representative to the Milan-based company’s board of directors. At closing of the deal, the Neuronova shareholders will represent a holding of 33% in Newron’s share capital. For them, the transaction is a bid on the positive development of NeuroNova’s  compounds. “We value Newron’s expertise in taking compounds from clinical stages to regulatory filing, and support the concept of building a European CNS player that could benefit both patients and our stakeholders”, stated Jakob Lindberg from Investor. “It is the logical next step to NeuroNova to combine our advanced pipeline and know-how, originally stemming from research at Karolinska Institute and developed by our team in the recent years, with a larger player in the CNS field”, added Ulf Ljungberg, President and CEO of NeuroNova, stating that the combined product portfolio represents “a strong platform on which to build the critical mass this industry is looking for.” 

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF111.2%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR98.1%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.8%
  • MERCK KGAA (D)63.67 EUR-50.5%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • IXICO (UK)55.50 GBP314.2%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.0%

No liability assumed, Date: 10.07.2014